Compare KTF & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KTF | AKBA |
|---|---|---|
| Founded | 1988 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 361.2M | 343.4M |
| IPO Year | N/A | 2014 |
| Metric | KTF | AKBA |
|---|---|---|
| Price | $8.78 | $0.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | 233.2K | ★ 4.8M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | ★ 0.39 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.63 | $0.81 |
| 52 Week High | $9.37 | $3.22 |
| Indicator | KTF | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 29.43 | 39.38 |
| Support Level | $8.76 | $0.85 |
| Resistance Level | $9.25 | $1.54 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 5.56 | 22.79 |
DWS Municipal Income Trust is a closed-ended fixed income mutual fund launched and managed by Deutsche Investment Management Americas, Inc. The company invests in the fixed income markets of the United States. The fund invests in investment-grade tax-exempt municipal securities which are exempt from federal income tax. The fund benchmarks the performance of its portfolio against the Barclays Municipal Bond Index. The Fund invests in various states, such as Texas, Florida, Pennsylvania, Illinois, and California.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.